Abstract | OBJECTIVE: METHODS: This study included 37 patients with refractory Behçet panuveitis unresponsive to conventional immunosuppressive therapy. Induction interferon alfa-2a therapy was given as a daily dose of 3.0 million IU (MIU) subcutaneously for 14 days. Maintenance dose was achieved with 3.0 MIU 3 times per week given subcutaneously. The dosage was increased sequentially to 4.5, 6.0, and 9.0 MIU 3 times per week if uveitis relapses occurred. Total therapy duration was 24 months. Primary outcome measure was control of uveitis with quiescence during maintenance therapy. Ocular relapses per patient-year before and after initiation of interferon alfa-2a therapy and a corticosteroid-sparing effect were secondary outcomes. We also estimated the rate of remission after discontinuing interferon alfa-2a therapy. RESULTS: CONCLUSION:
|
Authors | Sumru Onal, Haluk Kazokoglu, Aylin Koc, Mehmet Akman, Tayfun Bavbek, Haner Direskeneli, Sule Yavuz |
Journal | Archives of ophthalmology (Chicago, Ill. : 1960)
(Arch Ophthalmol)
Vol. 129
Issue 3
Pg. 288-94
(Mar 2011)
ISSN: 1538-3601 [Electronic] United States |
PMID | 21402983
(Publication Type: Journal Article)
|
Chemical References |
- Angiogenesis Inhibitors
- Interferon alpha-2
- Interferon-alpha
- Recombinant Proteins
|
Topics |
- Adolescent
- Adult
- Angiogenesis Inhibitors
(administration & dosage, adverse effects)
- Behcet Syndrome
(drug therapy, physiopathology)
- Female
- Fluorescein Angiography
- Follow-Up Studies
- Humans
- Injections, Subcutaneous
- Interferon alpha-2
- Interferon-alpha
(administration & dosage, adverse effects)
- Male
- Middle Aged
- Recombinant Proteins
- Treatment Outcome
- Visual Acuity
- Young Adult
|